ERBB2 and breast cancer: Moreover, patients with metastatic HER2 + breast cancer and a good prognosis exhibited a higher proportion of CD4 + IL-2 + T cells relative to CD4 + IL-4 + T cells, along with an increased percentage of CD56bright NK cells, in their peripheral blood compared to patients with a poor prognosis (Fig. 4D-E).